Brexanolone caprilcerbate
CAS 2681264-65-1
MFC48H78O12 MW 847.1 g/mol
1-O-[[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxycarbonyloxymethyl] 5-O-[1,3-di(octanoyloxy)propan-2-yl] 3-methylpentanedioate
1-[1,3-bis(octanoyloxy)propan-2-yl] 5-[({[(20-oxo-5α-pregnan3α-yl)oxy]carbonyl}oxy)methyl] 3-methylpentanedioate
GABAA receptor positive allosteric modulator, K3KLQ9T6WM, PHASE 2,
Brexanolone caprilcerbate (INNTooltip International Nonproprietary Name; developmental code names LYT-300, SPT-300) is an orally active prodrug of brexanolone (allopregnanolone) which is under development for the treatment of anxiety disorders.[1][2][3][4] It is a absorbed via the lymphatic system with oral administration.[5] The drug is being developed by Seaport Therapeutics and PureTech Health.[1][2] As of January 2025, it is in phase 2 clinical trials.[1]
SYN
https://patentscope.wipo.int/search/en/detail.jsf?docId=US335021515&_cid=P22-MKAJEO-33027-1
PAT
- Lipid prodrugs of neurosteroidsPublication Number: WO-2021159021-A1Priority Date: 2020-02-05
- Lipid prodrugs of neurosteroidsPublication Number: US-2023338552-A1Priority Date: 2020-02-05
- Lipid prodrugs of neurosteroidsPublication Number: US-2022395513-A1Priority Date: 2020-02-05
- Lipid prodrugs of neurosteroidsPublication Number: US-2021268115-A1Priority Date: 2020-02-05
AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
……
References
- “Allopregnanolone prodrug”. AdisInsight. 28 January 2025. Retrieved 26 February 2025.
- “Delving into the Latest Updates on Brexanolone caprilcerbate with Synapse”. Synapse. 15 February 2025. Retrieved 26 February 2025.
- “Proposed INN: List 131 International Nonproprietary Names for Pharmaceutical Substances (INN)” (PDF). WHO Drug Information. 38 (2): 270. 2024.
brexanolonum caprilcerbas brexanolone caprilcerbate 1-[1,3-bis(octanoyloxy)propan-2-yl] 5-[({[(20-oxo-5α-pregnan3α-yl)oxy]carbonyl}oxy)methyl] 3-methylpentanedioate GABAA receptor positive allosteric modulator C48H78O12 2681264-65-1
- Carlini SV, Osborne LM, Deligiannidis KM (December 2023). “Current pharmacotherapy approaches and novel GABAergic antidepressant development in postpartum depression”. Dialogues in Clinical Neuroscience. 25 (1): 92–100. doi:10.1080/19585969.2023.2262464. PMC 10557560. PMID 37796239.
- Alashal N, Hussain N (2025). “Approach to the use of rescue medications in children for prolonged epileptic seizures in the community”. Paediatrics and Child Health. 35 (4): 113–117. doi:10.1016/j.paed.2025.01.004.
| Clinical data | |
|---|---|
| Other names | LYT-300; LYT300; SPT-300; SPT300; Allopregnanolone 3-O-caprilcerbate |
| Routes of administration | Oral[1] |
| Drug class | GABAA receptor positive allosteric modulator; Neurosteroid |
| Identifiers | |
| IUPAC name | |
| CAS Number | 2681264-65-1 |
| PubChem CID | 158098654 |
| UNII | K3KLQ9T6WM |
| Chemical and physical data | |
| Formula | C48H76O12 |
| Molar mass | 845.124 g·mol−1 |
| 3D model (JSmol) | Interactive image |
| SMILES | |
| InChI | |
/////////////Brexanolone caprilcerbate, GABAA receptor positive allosteric modulator, K3KLQ9T6WM, PHASE 2,